Stockreport

Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

Amylyx Pharmaceuticals, Inc.  (AMLX) 
PDF Recruitment of the pivotal Phase 3 LUCIDITY trial of avexitide in PBH is complete; continue to expect to randomize and dose last eligible participants in Q1 2026, with t [Read more]